目的 探究氨溴索口服液聯(lián)合酮替芬治療小兒哮喘的臨床療效。方法 選取2013年1月-2015年1月在三六三醫(yī)院接受治療的小兒哮喘患兒83例，隨機(jī)分為對(duì)照組（41例）和治療組（42例）。對(duì)照組患兒口服富馬酸酮替芬片，3歲以下患兒0.5 mg/次，2次/d；3歲以上1 mg/次，2次/d。治療組患兒在對(duì)照組的基礎(chǔ)上口服鹽酸氨溴索口服液，1～2歲患兒2.5 mL/次，2次/d；2～6歲2.5 mL/次，3次/d；6～12歲5 mL/次，2～3次/d。兩組患兒均連續(xù)治療6周。觀察兩組患兒臨床療效，同時(shí)比較兩組患兒治療前后平喘時(shí)間、止咳時(shí)間、咳痰和肺部哮鳴音消失時(shí)間及癥狀復(fù)發(fā)率。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為73.17%、95.23%，兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組患兒的平喘時(shí)間、咳痰時(shí)間、止咳時(shí)間和肺部哮鳴音消失時(shí)間均顯著短于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療組3、6個(gè)月的復(fù)發(fā)率分別為2.3%、7.0%，顯著低于同期對(duì)照組的復(fù)發(fā)率，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 氨溴索口服液聯(lián)合酮替芬治療小兒哮喘可顯著縮短患兒平喘時(shí)間，止咳快且哮鳴音消失時(shí)間短，復(fù)發(fā)率低，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the curative effect of ambroxol oral solution combined with ketotifen in treatment of children asthma. Methods Children (83 cases) with asthma in 363 Hospital from January 2013 to January 2015 were randomly divided into control (41 cases) and treatment (42 cases) groups. Children in the control group were po administered with Ketotifen Fumarate Tablets, 0.5 mg/time for children under 3 years old, twice daily, and 1 mg/time for children above 3 years old, twice daily. Children in the treatment group were po administered with Ambroxol Hydrochloride Oral Solution on the basis of the control group, 2.5 mL/time for 1-2 years old children, twice daily. And 2.5 mL/time for 2-6 years old children, three times daily. And 5 mL/time for 6-12 years old children, 2-3 times daily. Children in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the disappearing time of asthma, cough, expectoration, and lung rale in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.17% and 95.23%, respectively, and there was difference between two groups (P<0.05). After treatment, the disappearing time of asthma, cough, expectoration, and lung rale in treatment group were significantly shorter than those in the control group, and there was difference between two groups (P<0.05). The 3 and 6 months recurrence rate of the treatment group were 2.3% and 7.0%, which were significantly lower than that in the same period of the control group, with significant difference between two groups (P<0.05). Conclusion Ambroxol oral solution combined with ketotifen in treatment of children asthma can significantly shorten the time of asthma, cough and wheezing with low recurrence rate, which has a certain clinical application value.